These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 30061363)
1. MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363 [No Abstract] [Full Text] [Related]
2. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676 [TBL] [Abstract][Full Text] [Related]
3. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906 [TBL] [Abstract][Full Text] [Related]
4. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799 [TBL] [Abstract][Full Text] [Related]
5. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841 [TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822 [TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423 [TBL] [Abstract][Full Text] [Related]
8. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921 [TBL] [Abstract][Full Text] [Related]
9. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163 [TBL] [Abstract][Full Text] [Related]
10. ALK2 inhibitors display beneficial effects in preclinical models of Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C Commun Biol; 2019; 2():156. PubMed ID: 31098401 [TBL] [Abstract][Full Text] [Related]
11. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157 [TBL] [Abstract][Full Text] [Related]
12. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016 [TBL] [Abstract][Full Text] [Related]
13. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119 [TBL] [Abstract][Full Text] [Related]
14. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma. Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969 [TBL] [Abstract][Full Text] [Related]
16. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429 [TBL] [Abstract][Full Text] [Related]